Table 6.
Investigators | n | Stress Agent | Sensitivity (%) | Specificity (%) |
---|---|---|---|---|
Baer et al.150 | 23 | Dipyridamole | 78 | NA |
Baer et al.151* | 32 | Dobutamine | 84 | NA |
Hundley et al.149 | 41 | Dobutamine and atropine | 83 | 83 |
Jahnke et al.152 | 40 | Dobutamine | 89 | 75 |
Nagel et al.148 | 172 | Dobutamine | 86 | 86 |
Paetsch et al.153 | 79 | Adenosine | 91 | 62 |
Paetsch et al.153 | 79 | Dobutamine and atropine | 89 | 81 |
Paetsch et al.154 | 150 | Dobutamine | 78 | 88 |
Pennell et al.155 | 40 | Dipyridamole | 62 | 100 |
Pennell et al.156 | 25 | Dobutamine | 91 | 100 |
Rerkpattanapipat et al.157 | 27 | Exercise | 79 | 85 |
Schalla et al.158 | 22 | Dobutamine | 81 | 83 |
van Rugge et al.159 | 45 | Dobutamine | 81 | 100 |
van Rugge et al.160 | 39 | Dobutamine | 91 | 0.83 |
CMR indicates cardiovascular magnetic resonance; and NA, not available.
Utilized 2 perfusion territories (left anterior descending coronary artery and combined left circumflex artery/right coronary artery).
Modified from Nandalur et al.146